Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

被引：3

作者：

Sauter, Craig S. ^{[1
]}

Riviere, Isabelle ^{[1
]}

Bernal, Yvette J. ^{[1
]}

Wang, Xiuyan ^{[1
]}

Purdon, Terence J. ^{[1
]}

Yoo, Sarah ^{[1
]}

Moskowitz, Craig H. ^{[1
]}

Giralt, Sergio ^{[1
]}

Matasar, Matthew J. ^{[1
]}

Curran, Kevin J. ^{[1
]}

Park, Jae H. ^{[1
]}

Sadelain, Michel ^{[1
]}

Brentjens, Renier J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
Liang, Aibin
Zhou, Lili
Li, Ping
Yu, Wenjuan
Yang, Min
Xu, Yangyang
Ye, Shiguang
Zhu, Judy
Huang, Jiaqi
Zhang, Yan
Li, Lanfang
Zhao, Jing
Li, Jing
Zheng, Chengxiao
Zhu, Kevin
Lan, Liping
Zhang, Huilai
Zhou, Daobin
Yao, Yihong
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)
Wei, J. I. A.
Xiao, Min
Mao, Zekai
Cao, Yang
Xiao, Yi
Meng, Fankai
Zhang, Yicheng
Zhou, Jianfeng
Huang, Liang
BLOOD, 2021, 138
[23] Results of the phase I transcend NHL 001 trial of JCAR017 support the phase II transcend world study of this Chimeric Antigen Receptor (CAR) T-Cell therapy in patients (Pts) with aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)
Borchmann, P.
Viardot, A.
Wermke, M.
Subklewe, M.
Siddiqi, T.
Jaeger, U.
Hasskarl, J.
Abramson, J. S.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 37 - 37
[24] Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
Korell, Felix
Schubert, Maria-Luisa
Sauer, Tim
Schmitt, Anita
Derigs, Patrick
Weber, Tim Frederik
Schnitzler, Paul
Mueller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
CANCERS, 2021, 13 (07)
[25] CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas
Cao, Yang
Xiao, Yi
Wang, Na
Wang, Gaoxiang
Huang, Liang
Hong, Zhenya
Meng, Li
Zhou, Xiaoxi
Wang, Jue
Yang, Yang
Xu, Hao
Zhang, Shangkun
Xiao, Min
Chen, Liting
Zheng, Miao
Li, Chunrui
Mao, Xia
Gu, Chaojiang
Zhang, Tongcun
Zhang, Yicheng
Zhou, Jianfeng
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11): : 910.e1 - 910.e11
[26] Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Hirayama, Alexandre V.
Gauthier, Jordan
Hay, Kevin A.
Voutsinas, Jenna M.
Wu, Qian V.
Gooley, Ted
Li, Daniel
Sheih, Alyssa
Purushe, Janaki
Cherian, Sindhu
Chen, Xueyan
Pender, Barbara S.
Hawkins, Reed M.
Vakil, Aesha
Steinmetz, Rachel N.
Tinh-Doan Phi
Lynch, Ryan C.
Chapuis, Aude G.
Till, Brian G.
Kiem, Hans-Peter
Ramos, Jorge
Shadman, Mazyar
Cassaday, Ryan D.
Acharya, Utkarsh H.
Riddell, Stanley R.
Maloney, David G.
Turtle, Cameron J.
BLOOD, 2018, 132
[27] Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center
Carpio, Cecilia
Iacoboni, Gloria
Villacampa, Guillermo
Catala, Eva
Bobillo, Sabela
Perez, Ana
Jimenez, Moraima
Segura, Laura
Olive, Mireia
Farriols, Anna
Abrisqueta, Pau
Valcarcel, David
Carreras, Maria Josep
Bosch, Francesc
Barba, Pere
LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2288 - 2291
[28] CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL
Park, Jae H.
Riviere, Isabelle
Wang, Xiuyan
Bernal, Yvette J.
Yoo, Sarah
Purdon, Terrence
Halton, Elizabeth
Quintanilla, Hilda
Curran, Kevin J.
Sauter, Craig S.
Davila, Marco L.
Sadelain, Michel
Brentjens, Renier J.
BLOOD, 2014, 124 (21)
[29] Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children
Del Bufalo, Francesca
Quintarelli, Concetta
De Angelis, Biagio
Caruana, Ignazio
Sinibaldi, Matilde
Vinti, Luciana
Merli, Pietro
Algeri, Mattia
Ruggeri, Annalisa
Galaverna, Federica
Cirillo, Valentina
Cefalo, Maria Giuseppina
Pira, Giuseppina Li
Leone, Giovanna
Bertaina, Valentina
Fassio, Franca
Gunetti, Monica
Iacovelli, Stefano
Locatelli, Franco
BLOOD, 2019, 134
[30] Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.
Gauthier, Jordan
Hirayama, Alexandre V.
Hay, Kevin Anthony
Li, Daniel
Sheih, Alyssa
Wu, Vicky
Voutsinas, Jenna M.
Cherian, Sindhu
Chen, Xueyan
Pender, Barbara S.
Hawkins, Reed M.
Vakil, Aesha
Tinh-Doan Phi
Steinmetz, Rachel N.
Riddell, Stanley R.
Maloney, David G.
Turtle, Cameron
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →